Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281660797> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4281660797 endingPage "e19532" @default.
- W4281660797 startingPage "e19532" @default.
- W4281660797 abstract "e19532 Background: The traditional approach to the treatment of early-stage classical Hodgkin lymphoma (cHL) has been combined modality therapy (CMT) with both chemotherapy and radiotherapy (RT). CMT has shown improved disease control, but RT can lead to long-term adverse effects, including secondary malignancies and cardiac toxicity. Multiple clinical trials have assessed treatment de-escalation strategies to chemotherapy-alone regimens, but results are conflicting. We aimed to assess the real-world implications of these trials by comparing patient outcomes based upon treatment with CMT or chemotherapy-alone. Furthermore, we proposed to assess differences in treatment outcomes stratified by disease bulk, favorable/unfavorable disease, and PET2 response. Methods: We conducted a retrospective, multi-center cohort study of consecutive adult patients with early-stage (stage IA-IIB) cHL treated between January 2010-December 2020. Baseline characteristics, treatment modality, and outcomes were abstracted by chart review. Available PET2 scans (n=110) were independently reviewed by a blinded nuclear radiologist. Deauville score (DS) ≥4 was characterized as positive (+), and DS≤3 negative (-). All analysis was conducted using intention-to-treat principles based upon the initial treatment plan (CMT or chemotherapy-alone). Results: In 125 patients [58% male, median age 34 (range, 18-78)] with early-stage cHL, CMT was intended in 63 (50%) patients, with chemotherapy-alone in 62 (50%). Bulky disease was observed in 43 (34%), unfavorable disease in 81 (65%), and 15 (14%) were found to be PET2+. With median follow-up of 59.8 months (95%CI, 48.6 to 71.0), 5 (4%) deaths occurred, and 17 (14%) patients had relapsed/refractory disease. No significant differences in overall survival (OS) were seen based upon treatment intention. However, there was substantially reduced progression-free survival (PFS) (Table) with chemotherapy-alone in the whole cohort, and also in those with bulky, unfavorable, and PET2+ disease. No significant PFS differences were seen based upon treatment intention for patients with non-bulky, favorable, or PET2- disease. Conclusions: Based on our real-world experience, CMT appears particularly beneficial for patients with bulky disease, unfavorable prognostic factors, and PET2+ disease. However, while recent trials showed a benefit of CMT in non-bulky, favorable and PET2- patients, chemotherapy-alone may be comparable for these patients in actual clinical practice.[Table: see text]" @default.
- W4281660797 created "2022-06-13" @default.
- W4281660797 creator A5025688165 @default.
- W4281660797 creator A5026397451 @default.
- W4281660797 creator A5032001510 @default.
- W4281660797 creator A5048644166 @default.
- W4281660797 creator A5051399808 @default.
- W4281660797 creator A5057100726 @default.
- W4281660797 creator A5059729547 @default.
- W4281660797 creator A5076892547 @default.
- W4281660797 creator A5078705257 @default.
- W4281660797 creator A5081170659 @default.
- W4281660797 creator A5087231813 @default.
- W4281660797 date "2022-06-01" @default.
- W4281660797 modified "2023-09-29" @default.
- W4281660797 title "Combined modality therapy for early-stage Hodgkin lymphoma in the PET era: A real-world study." @default.
- W4281660797 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e19532" @default.
- W4281660797 hasPublicationYear "2022" @default.
- W4281660797 type Work @default.
- W4281660797 citedByCount "0" @default.
- W4281660797 crossrefType "journal-article" @default.
- W4281660797 hasAuthorship W4281660797A5025688165 @default.
- W4281660797 hasAuthorship W4281660797A5026397451 @default.
- W4281660797 hasAuthorship W4281660797A5032001510 @default.
- W4281660797 hasAuthorship W4281660797A5048644166 @default.
- W4281660797 hasAuthorship W4281660797A5051399808 @default.
- W4281660797 hasAuthorship W4281660797A5057100726 @default.
- W4281660797 hasAuthorship W4281660797A5059729547 @default.
- W4281660797 hasAuthorship W4281660797A5076892547 @default.
- W4281660797 hasAuthorship W4281660797A5078705257 @default.
- W4281660797 hasAuthorship W4281660797A5081170659 @default.
- W4281660797 hasAuthorship W4281660797A5087231813 @default.
- W4281660797 hasConcept C126322002 @default.
- W4281660797 hasConcept C141071460 @default.
- W4281660797 hasConcept C143998085 @default.
- W4281660797 hasConcept C146357865 @default.
- W4281660797 hasConcept C151730666 @default.
- W4281660797 hasConcept C167135981 @default.
- W4281660797 hasConcept C197934379 @default.
- W4281660797 hasConcept C2776694085 @default.
- W4281660797 hasConcept C2779134260 @default.
- W4281660797 hasConcept C2779338263 @default.
- W4281660797 hasConcept C509974204 @default.
- W4281660797 hasConcept C535046627 @default.
- W4281660797 hasConcept C71924100 @default.
- W4281660797 hasConcept C86803240 @default.
- W4281660797 hasConceptScore W4281660797C126322002 @default.
- W4281660797 hasConceptScore W4281660797C141071460 @default.
- W4281660797 hasConceptScore W4281660797C143998085 @default.
- W4281660797 hasConceptScore W4281660797C146357865 @default.
- W4281660797 hasConceptScore W4281660797C151730666 @default.
- W4281660797 hasConceptScore W4281660797C167135981 @default.
- W4281660797 hasConceptScore W4281660797C197934379 @default.
- W4281660797 hasConceptScore W4281660797C2776694085 @default.
- W4281660797 hasConceptScore W4281660797C2779134260 @default.
- W4281660797 hasConceptScore W4281660797C2779338263 @default.
- W4281660797 hasConceptScore W4281660797C509974204 @default.
- W4281660797 hasConceptScore W4281660797C535046627 @default.
- W4281660797 hasConceptScore W4281660797C71924100 @default.
- W4281660797 hasConceptScore W4281660797C86803240 @default.
- W4281660797 hasIssue "16_suppl" @default.
- W4281660797 hasLocation W42816607971 @default.
- W4281660797 hasOpenAccess W4281660797 @default.
- W4281660797 hasPrimaryLocation W42816607971 @default.
- W4281660797 hasRelatedWork W1535958986 @default.
- W4281660797 hasRelatedWork W2053205102 @default.
- W4281660797 hasRelatedWork W2112851763 @default.
- W4281660797 hasRelatedWork W2355670240 @default.
- W4281660797 hasRelatedWork W2362144381 @default.
- W4281660797 hasRelatedWork W2376593068 @default.
- W4281660797 hasRelatedWork W2411610896 @default.
- W4281660797 hasRelatedWork W2431435345 @default.
- W4281660797 hasRelatedWork W4220939315 @default.
- W4281660797 hasRelatedWork W4291189777 @default.
- W4281660797 hasVolume "40" @default.
- W4281660797 isParatext "false" @default.
- W4281660797 isRetracted "false" @default.
- W4281660797 workType "article" @default.